CN2 Stock Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Catalyst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.80 |
| 52 Week High | US$16.18 |
| 52 Week Low | US$10.43 |
| Beta | 0.88 |
| 1 Month Change | 1.44% |
| 3 Month Change | 11.24% |
| 1 Year Change | -2.66% |
| 3 Year Change | 298.57% |
| 5 Year Change | 209.20% |
| Change since IPO | 1,652.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| CN2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.6% | -4.9% | -1.5% |
| 1Y | -2.7% | -19.9% | 0.9% |
Return vs Industry: CN2 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: CN2 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| CN2 volatility | |
|---|---|
| CN2 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CN2 has not had significant price volatility in the past 3 months.
Volatility Over Time: CN2's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 167 | Rich Daly | www.catalystpharma.com |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
Catalyst Pharmaceuticals, Inc. Fundamentals Summary
| CN2 fundamental statistics | |
|---|---|
| Market cap | €1.77b |
| Earnings (TTM) | €67.09m |
| Revenue (TTM) | €374.11m |
25.4x
P/E Ratio4.5x
P/S RatioIs CN2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CN2 income statement (TTM) | |
|---|---|
| Revenue | US$398.20m |
| Cost of Revenue | US$145.12m |
| Gross Profit | US$253.09m |
| Other Expenses | US$181.68m |
| Earnings | US$71.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 63.56% |
| Net Profit Margin | 17.93% |
| Debt/Equity Ratio | 0% |
How did CN2 perform over the long term?
See historical performance and comparison